Patent ID: 7422745
Filing Date: 2008-09-09
Classification: A61K,C07K

Abstract:
1. A method of treating cancer, comprising contacting α v β 3 with an antibody or a functional fragment thereof, comprising 6 CDRs wherein said antibody or functional fragment comprises a V H CDR1 selected from SEQ ID NOs: 48, 50, and 52; a V H CDR2 selected from SEQ ID NOs:54, 56, and 58; a V H CDR3 selected from SEQ ID NOs: 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 94, 96, 98 and 100; a V L CDR1 having SEQ ID NO:82; a V L CDR2 having SEQ ID NO:84; and a V L CDR3 selected from SEQ ID NOs:86, 88, 90 and 92, said antibody or functional fragment thereof having integrin α v β 3 binding activity, integrin α v β 3 binding specificity or integrin α v β 3 inhibitory activity.